Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Editas Medicine Makes New Appointments

This article was originally published in Scrip

Executive Summary

Genome editing company, Editas Medicine, has appointed Timothy D. Hunt senior vice president of corporate affairs and Haiyan Jiang vice president of preclinical science. Hunt joins Editas from Cubist Pharmaceuticals where he was senior vice president of public affairs, before it was acquired by Merck last year. Jiang started her career as a scientist at Avigen and before joining Editas, she was senior director of cell and gene therapy at Biogen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register